Cisplatin reduces costs and provides more quality adjusted life years (QALYs) than cetuximab in chemoradiotherapy for patients with HPV-positive oropharyngeal cancer (HPV+OPC)
Jones DA., Mehanna H., Mistry P., Dalby M., Fulton-Lieuw T., Kong AH., Dunn J., Gray A.